Upon joining the study, the participant will be required to sign an informed consent form. This document confirms understanding and agreement to follow the study’s requirements.

An initial assessment will be conducted to confirm eligibility. This includes verifying age, weight, and a clinical diagnosis of non-segmental vitiligo.

Participants must have previously tried at least one topical treatment for vitiligo without success or have signs of actively progressing vitiligo.

Participants will receive either upadacitinib or a placebo. Upadacitinib is administered as a modified-release tablet taken orally.

The dosage and frequency of administration will be determined by the study protocol.

Throughout the study, regular assessments will be conducted to monitor the effectiveness and safety of the treatment.

These assessments will include measurements of vitiligo area and severity index (VASI) to track changes in skin condition.

The primary evaluation will occur at Week 48. The goal is to achieve a significant reduction in vitiligo severity, measured by T-VASI 50 and F-VASI 75.

Secondary evaluations will also be conducted, focusing on additional improvements in vitiligo severity and participant-reported outcomes.

These evaluations will occur at various points, including Week 24 and Week 48.

The study is expected to conclude by February 2028. Participants will receive a final assessment to determine the overall effectiveness and safety of the treatment.